Concerning the Diagnostic and Treatment Problems of Children with Pneumonia
https://doi.org/10.15690/pf.v12i3.1365
Abstract
Background: Pneumonia is one of the most frequent serious potentially life threatening childhood diseases. The criteria for diagnostics and treatment were designed long ago and are clearly articulated. Nevertheless, diagnostics and therapy happen most often during outpatient management.
Objective: The aim was to compare the diagnostic criteria of CAP among children in Russian and foreign guidelines and also to compare the incidence. Another aim is to find out the aptness to the Russian guidelines for the management of CAP among children.
Materials and methods: The comparative analysis of childhood pneumonia diagnostics and treatment guidelines have been recently published in a range of countries. We reviewed some recently published pneumonia recommendations. The timeliness and adequacy of hospitalization and treatment was analyzed for 167 hospitalized children with pneumonia diagnosed according to Russian and WHO recommendations. We also used the information about the quality of X-ray pneumonia diagnosis in 679 patients from hospitals in Barnaul, Ekaterinburg and Murmansk (PAPIRUS research project).
Results: We found a high percentage of late (5-th day and later) hospitalization of children with pneumonia (37 percent in 2002–2007 and 47 percent in 2013–2014) as well as a late ( 5 days) start of therapy (20 and 34 percent accordingly). In three regional hospitals only 27 percent of X-ray films of children treated for pneumonia were attested as meeting the pneumonia criteria. We found a high frequency of macrolides as a starting therapy in typical pneumonia which often had been ineffective. Amoxicillin/clavulanate and oral cephalosporins were also ineffective in doses < 45 mg/kg/day. A poor knowledge of the clinical features of atypical pneumonia was noted with a corresponding high frequency of -lactams as a starting medication.
Conclusion. Our data shows the importance of training paediatricians in modern pneumonia diagnosis and treatment.
About the Authors
M. D. Bakradze
Scientific Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
D. D. Gadliya
Scientific Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
O. A. Rogova
Scientific Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
T. A. Khokhlova
Scientific Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
V. K. Tatochenko
Scientific Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Баранов А.А., Таточенко В.К., Бакрадзе М.Д. Лихорадочные синдромы у детей. Рекомендации по диагностике и лечению. Москва: Союз педиатров России. 2011. 228 с.
2. Bradley J.S. et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the nfectious diseases society of America. Clin Infect Dis. 2011; 53 (7): 617–630.
3. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011; 66 (2): 1–23.
4. Queen M.A., Myers A.L., Hall M. et al Comparative Effectiveness of Empiric Antibiotics for Community-Acquired Pneumonia. Pediatrics. 2014; 133: e23–e29.
5. Spuesens E.B., Fraaij P.L., Visser E.G. et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2013; 10 (5): e1001444. Doi: 10.1371/journal.pmed.1001444. Epub 2013 May 14.
6. Cevey-Macherel M., Galetto-Lacour A., Gervaix A. et al. Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. Eur J Pediatr. 2009; 168: 1429.
7. Спичак Т.В. Критерии диагностики и соответствие лечения внебольничной пневмонии у детей современным стандартам. Вопросы диагностики в педиатрии. 2010; 2 (6): 31–34.
8. Баранов А.А. Клинические рекомендации по педиатрии. Под ред. А.А. Баранова. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа. 2009. 432 с.
9. ВОЗ. Оказание стационарной помощи детям. Карманный справочник. 2-е изд. Всемирная Организация Здравоохранения. Европа. 2006. 404 с.
10. Козлов Р.С., Кречикова О.И., Миронов К.О. с соавт. Результаты исследования распространенности в России внебольничной пневмонии и острого среднего отита у детей в возрасте до 5 лет (PAPIRUS). Роль S. pneumoniaе и H. influenzaе в этиологии данных заболеваний. Клин. микробиол. антимикроб. химиотер. 2013; 15 (4): 246–260.
11. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Community-acquired bacterial pneumonia: developing drugs for treatment 2009. URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm123686.pdf
12. Домбровская Ю.Ф. с соавт. Проект классификации клинических форм бронхолегочных заболеваний неспецифической этиологии у детей. Педиатрия. 1973; 9: 3–7.
13. Классификация клинических форм бронхолегочных заболеваний у детей. Вестник перинатол. и педиатрии. 1996; 41 (6): 52–55.
14. Геппе Н.А., Розинова Н.Н., Волков И.К., Мизерницкий Ю.Л. Новая рабочая классификация основных клинических форм бронхолегочных заболеваний у детей. Трудный пациент. 2009; 1 (2).
15. WHO Pneumococcal Vaccine Trial Investigation Group. Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. http://www.who.int/bulletin/volumes/83/5/353.pdf
16. Black S., Shinefield H.R., Ray P. et al. Efficacy of heptavalent conjugate pneumococcal vaccine in 37 000 infants and children: impact on pneumonia: otitis media and an update of the disease results in northern California. In: 39th Interscience Conference, Sept. 26–29, 1999, Washington D.C. Aqmerican Society for Microbiology. 1999; 379 (# 1398).
17. Clark J.E., Hammal D., Hampton F. et al. Epidemiology of community-acquired pneumonia in children seen in hospital. Epidemiol Infect. 2007; 135: 262e9.
18. Weigl J. 21th Annual Meeting of ESPID. Taormina, Sicily. 2003 April 9–12; abstr. 47: 24.
19. Bamba M., Jozaki K., Sugaya N. et al. Prospective surveillance for atypical pathogens in children with community-acquared pneumonia in Japan. Infect Chemother. 2006; 12 (1): 36–41.
20. Ибрагимова Ж.Р. Внебольничные пневмонии у детей дошкольного возраста, вызванные атипичными возбудителями. Оптимизация диагностики и терапии. Автореф. дис. …канд. мед. наук. Казань. 2014. 22 с.
21. Таточенко В.К. Острые пневмонии у детей. Чебоксары. 1994. 323 с.
22. Klugman K.P., Lonks J.R. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis. 2005; 11: 802–807.
23. Ovetchkine P. Rieder M.J. Canadian Paediatric Society. Azithromycin use in paediatrics: a practical overview. Paediatr Child Health. 2013; 18: 311–316.
24. Daneman N., McGeer A., Green K., Low D.E. Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis. 2006; 43: 432–438.
Review
For citations:
Bakradze M.D., Gadliya D.D., Rogova O.A., Khokhlova T.A., Tatochenko V.K. Concerning the Diagnostic and Treatment Problems of Children with Pneumonia. Pediatric pharmacology. 2015;12(3):354-359. https://doi.org/10.15690/pf.v12i3.1365
Views:
1355
Email this article 